Du Ying

CEO/then-Chair Du Ying sold 100,000 ZLAB shares for $1,986,875 via scheduled 10b5-1 plan; stock down 58.6% YTD, company unprofitable with $-51.0M net loss

Du Ying, who was Chairperson & CEO at the time of filing, executed 2 separate sales totaling 100,000 shares for $1,986,875.00 on May 15 and May 18, 2026 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-11, reducing holdings by 8.2% to 1,122,626 shares. The sales occurred as ZLAB's stock trades at $18.37, down 58.6% from its 52-week high of $44.34, with 30-day and 90-day declines of 24.1% and 9.0% respectively, while the company reported negative net income of $-51,016,000.00 against quarterly revenue of $99,611,000.00. His prior 5 sales at ZLAB (March 2026) all showed positive 30-day and 90-day returns, contrasting with the steep post-transaction decline now underway. The scheduled-plan nature of this filing precludes timing characterization, but the backdrop of significant stock deterioration and persistent unprofitability warrants investor attention to the company's fundamental trajectory and capital allocation.

ZLAB CEO Du Ying sells 100,000 shares for $2.0M via scheduled 10b5-1 plan; stock down -11.4% in 30 days, -53.6% from 52-week high.

Du Ying executed 5 separate sales totaling 100,000 shares for $2,003,044.43 on 2026-05-13 and 2026-05-14 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-11, reducing her holdings from 1.22M shares to 1.12M shares. The transaction is scheduled and non-discretionary; pricing varied significantly across tranches (from $1.74 to $20.22 per share), reflecting market conditions during the execution window. The company is unprofitable (net income $-51,016,000.00), though revenue stands at $99,611,000.00 with annual growth of +15.3%. At current price of $20.59, the stock trades -53.6% from its 52-week high of $44.34 and is down -11.4% over the prior 30 days, a sharp decline from where some of these shares were sold.

ZLAB CEO Du Ying sold 100,000 shares for $1,922,400.00 in 2 transactions; stock down 54.8% from 52-week high.

Du Ying, the Chairperson & CEO, executed 2 separate sales totaling 100,000 shares for $1,922,400.00 on 2026-03-06 and 2026-03-09, reducing holdings from 1,064,161 to 964,161 shares. The blended average price of $19.22 reflects modest transaction prices relative to ZLAB's 52-week range of $16.30–$43.03; the current price of $19.46 sits 54.8% below the 52-week high. At the same-ticker level, Du Ying's prior 2 measurable sales (August 2025) both registered negative 90-day returns (-38.0% and -36.1%), demonstrating well-timed execution ahead of declines. The company carries negative net income of $-35,963,000.00 on quarterly revenue of $116,095,000.00, operating at a loss despite 15.3% annual revenue growth. The consecutive sales within 3 days warrant observation of broader intent given the unprofitable operational profile.

Du Ying sells 100,000 ZLAB shares for $1.9M; 4 of 4 prior ZLAB sales showed negative 90-day returns

Du Ying, Chairperson & CEO of Zai Lab, executed 3 separate sales totaling 100,000 shares (100.0K shares) for $1,919,208.40 ($1.9M) between March 4–5, 2026, reducing holdings from 1,064,161 shares (1.06M shares) to 964,161 shares (964.2K shares). His prior trades at ZLAB show a consistent pattern: 4 of 4 measurable prior sales at this ticker delivered negative 90-day returns, ranging from -33.4% to -38.0%, indicating his historical ZLAB sales preceded subsequent stock declines. The company remains unprofitable with net income of $-35,963,000.00 ($-36.0M) in its latest period, though revenue grew +15.3% year-over-year to $116,095,000.00 ($116.1M). Against this backdrop, the filing documents scheduled insider sales by a key executive immediately following a 52-week range pattern in which current price ($19.54) sits -54.6% from the 52-week high ($43.03).

ZLAB CEO Du Ying sells 96,387 shares for $3,357,841.59; cross-ticker track record shows well-timed sells (52.94% rate) but same-ticker history shows poor 90d outcomes.

Du Ying executed 2 separate sales totaling 96,387 shares for $3,357,841.59 on August 12–13, 2025, reducing holdings by 15.2% from 633,349 shares to 536,962 shares post-transaction. The blended average price of $34.84 falls near the current price of $34.93, suggesting limited post-sale appreciation. Across all tickers, Du Ying's prior 20 open-market sells achieved a 52.94% well-timed rate with a 90-day average return of 4.2%—indicating a modest pattern of selling ahead of weakness. However, at this specific ticker (ZLAB), his 2 prior sells with measurable 90-day outcomes both posted gains (19.0% and 22.2%), the inverse of well-timed sales; the most recent measurable same-ticker sale on 2025-06-26 returned only 2.9% at 30 days. The company remains unprofitable (net income $-40.7M on revenue of $110.0M), though it posted strong 49.6% annual revenue growth. The timing context here is mixed: cross-ticker track record suggests competence in sell-timing, but same-ticker history at ZLAB shows the opposite pattern.

ZLAB CEO Du Ying sold 100,000 shares for $3,468,970.00 (2 sales at blended avg $34.69)

Du Ying, Chairperson & CEO of Zai Lab Ltd, executed 2 separate open-market sales totaling 100,000 shares for $3,468,970.00 on 2025-08-08 and 2025-08-11, reducing his post-transaction holdings from 637.0K to 537.0K shares (-15.7%). The company is unprofitable (net income $-40,727,000.00 in the latest period) despite strong revenue growth of +49.6% year-over-year. At ZLAB specifically, his prior 3 measurable sales (all on 2025-05-13 and 2025-05-14) showed 90-day returns of +20.0%, +19.0%, and +22.2% — meaning the stock rose significantly after each sale, indicating those prior sales were not well-timed relative to subsequent price appreciation. The current stock price of $34.31 is 20.3% below the 52-week high of $43.03; the two sales occurred at $34.74 and $34.64, near recent lows relative to that range. This filing warrants monitoring to track whether the current sale aligns with the pattern established by his prior ZLAB sales.

ZLAB CEO Du Ying sold 23,669 shares at $36.13 on 2025-06-26; stock down 19.3% from 52-week high.

Du Ying's sale of 23,669 shares (23.7K shares) at $36.13 represents a 4.4% reduction in holdings at a price 19.3% below the 52-week high of $43.03. The timing is noteworthy: his prior 5 trades at ZLAB (all in May 2025) occurred near the peak, with subsequent 30-day gains of +40.6% to +50.7%, suggesting strong positioning before the recent decline. His cross-ticker track record shows 19 prior sells with a 90-day well-timed rate of 100.00%, though outcomes at ZLAB are not yet measurable at the 90-day horizon. The company is unprofitable (net income $-48.4M in the latest quarter) with strong revenue growth of +49.6% year-over-year, creating a pattern consistent with early-stage biotech selling strength into execution risk.

ZLAB CEO Du Ying sold 96,389 shares for $2,731,506.99 (blended avg $28.34) on May 13-14; post-sale holdings 479,851 shares (-16.7% net)

Du Ying, Chairperson & CEO of Zai Lab, executed 4 separate sales totaling 96,389 shares for $2,731,506.99 over two trading days (May 13-14), reducing his holdings by 16.7%. The company remains unprofitable with a net income of $-48,438,000.00 despite posting strong annual revenue growth of +49.6%, indicating continued cash burn despite top-line scaling. The sales occurred near the 52-week high (current price $28.75 is -25.0% from the $38.35 peak), and he retains substantial ownership at 479,851 shares post-transaction. At the same ticker, his 5 prior recent trades (clustered around early May and March) show one measurable outcome of -9.7% over 30 days from the March 5 sell, though most are too recent to assess performance. His broader cross-ticker track record shows 15 prior sells with an average 30-day return of +6.2%, suggesting his recent sales have not historically preceded immediate declines.

CEO Du Ying sells 100,000 ZLAB shares for $2,953,307.66 across 4 transactions, reducing stake by 17.2%.

Du Ying, Chairperson & CEO of Zai Lab Ltd (ZLAB), executed 4 separate sales totaling 100,000 shares for $2,953,307.66 at a blended average price of $29.53 per share on 2025-05-09 and 2025-05-12. This sale reduced his holdings from 579,851 shares to 479,851 shares, representing a -17.2% reduction in his stake. The timing occurs when the stock trades at $28.62 (down 25.4% from its 52-week high of $38.35 and down 3.1% over the prior 30 days), and the company remains unprofitable with a negative full-year net income of $-48,438,000.00 despite strong annual revenue growth of +49.6%. His prior trades at ZLAB show mixed near-term outcomes (including a -11.4% 30-day return on 2025-03-05), and this sale occurs during a period of weakness rather than at a peak valuation.

ZLAB CEO Du Ying sells 96,389 shares over 2 days (Mar 4–5) for $3,323,324.25 amid 16.3% stake reduction, amid +32.2% 30-day rally.

Du Ying (Chairperson & CEO) executed 5 separate sales totaling 96,389 shares for $3,323,324.25 between March 4–5, 2025, reducing his stake from 590,506 to 494,117 shares (-16.3% of pre-transaction holdings). The sales occurred across a narrow 2-day window at prices ranging from $32.69 to $35.84 (blended average $34.48), while the stock has risen +32.2% over the past 30 days and now trades at $35.39, within 1.4% of its 52-week high of $35.91. The company remains unprofitable (net income of -$41,671,000 for the latest quarter) despite strong revenue growth of +49.6% year-over-year and a $3.1B market cap. The timing of this large reduction in CEO ownership during the stock's steep recent climb and near its 52-week highs warrants investor attention to underlying catalysts and management's forward outlook.